var data={"title":"Nicardipine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nicardipine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6649?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nicardipine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nicardipine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=nicardipine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Nicardipine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201178\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cardene IV;</li>\n      <li>Cardene SR [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201215\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antianginal Agent;</li>\n      <li>\n        Antihypertensive;</li>\n      <li>\n        Calcium Channel Blocker;</li>\n      <li>\n        Calcium Channel Blocker, Dihydropyridine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201182\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Cardene SR has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Angina:</b> Immediate release: Oral: 20 mg 3 times daily; usual dosage: 20 to 40 mg 3 times daily (allow &ge;3 days between dose increases)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> Initial: 20 mg 3 times daily; usual dosage: 20 to 40 mg 3 times daily (allow &ge;3 days between dose increases)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sustained release:</i> Initial: 30 mg twice daily; usual dosage: 30 to 60 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute hypertension:</b> IV: Initial: 5 mg/hour; may increase by 2.5 mg/hour every 5 minutes (for rapid titration) to every 15 minutes (for gradual titration) up to a maximum of 15 mg/hour; adjust infusion rate as needed to maintain desired response; in rapidly titrated patients, consider reduction to 3 mg/hour after response is achieved. Discontinue infusion if unacceptable hypotension or tachycardia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Arterial hypertension in acute ischemic stroke (off-label use [Jauch 2013]):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patient otherwise eligible for reperfusion treatment (eg, alteplase) except blood pressure (BP) &gt;185/110 mm Hg:</i>  Initiate 5 mg/hour; titrate by 2.5 mg/hour at 5- to 15-minute intervals (maximum dose: 15 mg/hour). When goal BP obtained, adjust dose to maintain proper BP limits. If BP does not decline and remains &gt;185/110 mm Hg, alteplase should not be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Management of BP during and after reperfusion treatment (eg, alteplase) to maintain BP &le;180/105 mm Hg:</i> If  systolic BP &gt;180 to 230 mm Hg or diastolic &gt;105 to 120 mm Hg: Initiate 5 mg/hour; titrate by 2.5 mg/hour at 5- to 15-minute intervals (maximum dose: 15 mg/hour). If hypertension is refractory or diastolic BP &gt;140 mm Hg, consider other IV antihypertensives (eg, nitroprusside).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Substitution for oral therapy (approximate equivalents):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">20 mg every 8 hours oral, equivalent to 0.5 mg/hour IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">30 mg every 8 hours oral, equivalent to 1.2 mg/hour IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">40 mg every 8 hours oral, equivalent to 2.2 mg/hour IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Conversion to oral antihypertensive agent:</i> Initiate oral antihypertensive at the same time that IV nicardipine is discontinued; if transitioning to oral nicardipine, start oral nicardipine 1 hour prior to IV discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201183\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Initiate at the low end of the dosage range. Specific guidelines for adjustment of nicardipine are not available, but careful monitoring is warranted and adjustment may be necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201184\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Per the manufacturer: Initial:  20 mg 3 times daily (immediate release) or 30 mg twice daily (sustained release) with slow titration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; titrate slowly with careful monitoring; dosage adjustment may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201185\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Per the manufacturer: Initial: 20 mg twice daily (immediate release) with slow titration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; titrate slowly with monitoring; dosage adjustment may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201152\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 12 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardene SR: 30 mg [DSC] [contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardene SR: 60 mg [DSC] [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardene IV: 20 mg (200 mL); 40 mg (200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg/mL (10 mL); 25 mg/250 mL in Dextrose 5% (250 mL); 25 mg/250 mL in NaCl 0.9% (250 mL [DSC]); 50 mg/250 mL in NaCl 0.9% (250 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201138\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44524584\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Cardene SR has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201156\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: The total daily dose of immediate-release product may not automatically be equivalent to the daily sustained-release dose; use caution in converting. Administer without regards to meals; nicardipine sustained release administered with a meal may reduce the fluctuation in plasma levels. Do not chew or crush the sustained release formulation, swallow whole. Do not open or cut capsules. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Administer as a slow continuous infusion via central line or through a large peripheral vein. Peripheral  venous irritation may be minimized by changing the site of infusion every 12 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Premixed bags: Do not combine or run in the same line as other medications. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472949\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b>  25 mg in 250 mL (total volume) (concentration: 0.1 mg/mL) of D<sub>5</sub>W, D<sub>5</sub><sup>1</sup>/<sub>2</sub>NS, D<sub>5</sub>NS, D<sub>5</sub>W with KCl 40 mEq, NS, or <sup>1</sup>/<sub>2</sub>NS </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472950\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 100 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201155\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Angina:</b> Management of chronic stable angina (oral immediate-release product only)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Management of hypertension (oral immediate- and sustained-release products and IV); parenteral only for short-term use when oral treatment is not feasible or not desirable</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Guideline recommendations: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The 2014 guideline for the management of high blood pressure in adults (JNC 8) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients (JNC 8 [James 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &ge;60 years with systolic blood pressure (SBP) &ge;150 mm Hg or diastolic blood pressure (DBP) &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &lt;60 years with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &ge;18 years with diabetes with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &ge;18 years with chronic kidney disease (CKD) with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic kidney disease (CKD) and hypertension: In patients with chronic kidney disease (CKD), regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker instead of an ACEI or ARB.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Diabetes and hypertension: The American Diabetes Association (ADA) guidelines suggest that for patients with hypertension and diabetes <i>without</i> albuminuria, any of the 4 classes of blood pressure medications (eg, ACE inhibitors, angiotensin receptor blockers, thiazide-like diuretics, dihydropyridine calcium channel blockers) may be used and have shown beneficial cardiovascular outcomes (ADA 2017a).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730931\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Arterial hypertension in acute ischemic stroke; Control of blood pressure in patients with spontaneous intracranial hemorrhage; Migraines (prevention); Perioperative hypertension; Subarachnoid hemorrhage associated cerebral vasospasm</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201224\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NiCARdipine may be confused with niacinamide, NIFEdipine, niMODipine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardene may be confused with Cardizem, Cardura, codeine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cardene [US, Great Britain, Netherlands] may be confused with Cardem brand name for celiprolol [Spain]; Cardin brand name for simvastatin [Poland]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201145\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Flushing (6% to 10%), pedal edema (dose related; 7% to 8%), exacerbation of angina pectoris (dose related; 6%), hypotension (IV 6%), palpitations (3% to 4%), tachycardia (1% to 4%), chest pain (IV 1%), extrasystoles (IV 1%), hemopericardium (IV 1%), hypertension (IV 1%), supraventricular tachycardia (IV 1%), edema (&le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (6% to 15%), dizziness (4% to 7%), hypoesthesia (1%), intracranial hemorrhage (1%), pain (1%), somnolence (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaphoresis (1%), skin rash (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypokalemia (IV 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea and vomiting (IV 5%), nausea (2%), dyspepsia (&le;2%), abdominal pain (IV 1%), xerostomia (&le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Hematuria (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reaction (IV 1%), pain at injection site (IV 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (4% to 6%), myalgia (1%), paresthesia (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abnormal dreams, abnormal hepatic function tests, abnormal vision, angina pectoris, anxiety, arthralgia, atrial fibrillation (not distinguishable from natural history of atherosclerotic vascular disease), atrioventricular block, atypical chest pain, blurred vision, cerebral ischemia (not distinguishable from natural history of atherosclerotic vascular disease), confusion, conjunctivitis, constipation, deep vein thrombophlebitis, depression, depression of ST segment on ECG, dyspnea, ear disease, ECG abnormal, fever, gingival hyperplasia, heart block (not distinguishable from natural history of atherosclerotic vascular disease), hot flash, hyperkinesia, hypersensitivity reaction, hypertonia, hypophosphatemia, impotence, infection, insomnia, inversion T wave on ECG, malaise, myocardial infarction (chronic therapy; may be due to disease progression), neck pain, nervousness, nocturia, orthostatic hypotension, oxygen saturation decreased (possible pulmonary shunting), parotitis, pericarditis (not distinguishable from natural history of atherosclerotic vascular disease), peripheral vascular disease, respiratory tract disease, rhinitis, sinus node dysfunction (chronic therapy; may be due to disease progression), sinusitis, sore throat, sustained tachycardia, syncope, thrombocytopenia, tinnitus, tremor, urinary frequency, ventricular extrasystoles, ventricular tachycardia, vertigo, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201159\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to nicardipine or any component of the formulation; advanced aortic stenosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201142\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angina/MI: Increased angina (frequency, duration, or severity) and/or MI has occurred. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta blockade.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/syncope: Symptomatic hypotension with or without syncope may rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Avoid systemic hypotension in acute cerebral infarction or hemorrhage. Close monitoring of heart rate and blood pressure, especially during initial therapy and dosage titration, is required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral edema: A common side effect is peripheral edema (dose-dependent); occurs within 2 to 3 weeks of starting therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tachycardia: May occur; close monitoring of heart rate is required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aortic stenosis: Use with caution in patients with mild to moderate aortic stenosis; may reduce coronary perfusion resulting in ischemia. Use is contraindicated in patients with advanced aortic stenosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Use in patients with heart failure (HF) or severe left ventricular dysfunction, particularly with concomitant beta-blockade, may experience worsened symptoms of HF due to mild negative inotropic effects of nicardipine. The ACCF/AHA heart failure guidelines recommend to avoid use in patients with heart failure due to lack of benefit and/or worse outcomes with calcium channel blockers in general (Yancy 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment or reduced hepatic blood flow. Consider lower starting dose and closely monitor response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (ACCF/AHA [Gersh 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Increase dose cautiously in patients with renal impairment since clearance of nicardipine is diminished in this population.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion sites: To minimize infusion site reactions, peripheral infusion sites (for IV therapy) should be changed every 12 hours; use of arteries or small peripheral veins should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Abrupt withdrawal may cause rebound angina in patients with CAD.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201209\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, CYP2C9 (strong), CYP2D6 (weak), CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201147\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9697&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alitretinoin (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic).  Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP2C9 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP2C9 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.<b> Exceptions: </b>Fluconazole; Isavuconazonium Sulfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: NiCARdipine may enhance the hypotensive effect of Carvedilol. NiCARdipine may precipitate signs of heart failure in susceptible patients on Carvedilol NiCARdipine may increase the serum concentration of Carvedilol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of NiCARdipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: NiCARdipine may increase the serum concentration of Lacosamide.  Management: Lacosamide prescribing information cautions that a lacosamide dose reduction may be warranted in patients with renal dysfunction or mild-moderate hepatic impairment who are also using a strong inhibitor of CYP2C9 and CYP3A4, such as delavirdine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide.  Felodipine Canadian labeling specifically recommends avoiding its use in combination with clarithromycin.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parecoxib: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Parecoxib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Calcium Channel Blockers.  Management: Avoid use of nimodipine or nifedipine with phenytoin. Monitor for phenytoin toxicity and/or decreased calcium channel blocker effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramelteon: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some US and Canadian calcium channel blockers contraindicate use with rifampin, however recommendations vary. Consult appropriate labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUNItinib: NiCARdipine may increase the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201175\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Nicardipine average peak concentrations may be decreased if taken with food. Serum concentrations/toxicity of nicardipine may be increased by grapefruit juice. Management: Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201149\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201162\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Nicardipine has been used for the treatment of severe hypertension in pregnancy and preterm labor. Nicardipine crosses the placenta; changes in fetal heart rate, neonatal hypotension and neonatal acidosis have been observed following maternal use (rare; based on limited data). Adverse effects reported in pregnant women are generally similar to those reported in nonpregnant patients; however, pulmonary edema has been observed (Nij 2010). Untreated chronic maternal hypertension is also associated with adverse events in the fetus, infant, and mother. If treatment for hypertension during pregnancy is needed, other agents are preferred (ACOG 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9933181\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Nicardipine is minimally excreted in breast milk. In one study, peak milk concentrations ranged from 1.9 to 18.8 mcg/mL following oral maternal doses of 40 to 150 mg/day. The estimated exposure to the breast-feeding infant was calculated to be 0.073% of the weight-adjusted maternal oral dose or 0.14% of the weight-adjusted maternal IV dose. Breast-feeding is not recommended by some manufacturers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9601783\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9933182\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate; consult individual institutional policies and procedures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50404211\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension: </b>The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;60 years: Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &lt;60 years: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 years with diabetes: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 years with chronic kidney disease (CKD): Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes and hypertension: </b>The American Diabetes Association (ADA) guidelines (ADA 2017a; ADA 2017b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 to &le;65 years: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 to &le;65 years <b>and</b> at high risk of cardiovascular disease: Goal of therapy is SBP &lt;130 mm Hg and DBP &lt;80 mm Hg (if can be achieved without undue treatment burden).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;65 years (healthy <b>or </b>complex/intermediate health): Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;65 years (very complex/poor health): Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201141\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201158\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IV: Within minutes (constant infusion); Oral: 0.5 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Immediate capsules: 1 to 2 hours; Sustained release capsules (at steady state): Sustained from 2 to 6 hours postdose; IV continuous infusion: 50% of the maximum effect is seen by 45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: &le;8 hours; upon discontinuation of continuous infusion, a 50% decrease in effect is seen in ~30 minutes with gradual discontinuing antihypertensive effects for ~50 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release: &le;8 hours; Sustained release: 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: ~100%, but large first-pass effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 8.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; extensive first-pass effect (saturable); major pathway is via cytochrome P450 isoenzyme CYP3A4, 2C8, and 2D6.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: ~35%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Follows dose-dependent (nonlinear) pharmacokinetics; &ldquo;apparent&rdquo; or calculated half-life is dependent upon serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Half-life over the first 8 hours is 2 to 4 hours; terminal half-life: 8.6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: After IV infusion, serum concentrations decrease tri-exponentially; alpha half-life: 3 minutes; beta half-life: 45 minutes; terminal half-life: 14 hours (<b>Note:</b> Terminal half-life can only be seen after long-term infusions).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral:  Immediate release: 30 to 120 minutes (mean: 1 hour); Sustained release: 60 to 240 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (oral: 60% as metabolites; IV: 49% as metabolites; &lt;1% as unchanged drug); feces (oral: 35%; IV: 43%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Decreased in patients with hepatic impairment; may be decreased in patients with renal impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201161\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (NiCARdipine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $200.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (90): $287.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cardene IV Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/200 mL 0.86% (200 mL): $121.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/200 mL 4.8% (200 mL): $121.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/200 mL 0.83% (200 mL): $243.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/200 mL 5% (200 mL): $243.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (NiCARdipine HCl in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25MG/250ML 5% (250 mL): $64.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (NiCARdipine HCl in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MG/250ML 0.9% (250 mL): $93.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (NiCARdipine HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg/mL (10 mL): $24.17</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201163\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antagonil (DE);</li>\n      <li>Barizin (HR);</li>\n      <li>Binicapin (KR);</li>\n      <li>Blistra (ID);</li>\n      <li>Cardene (IE, NL);</li>\n      <li>Cardene SR (GB, NL);</li>\n      <li>Cardepine (MY);</li>\n      <li>Cardepine SR (MY);</li>\n      <li>Cardibloc SR (SG);</li>\n      <li>Cardibrain (TW);</li>\n      <li>Cardilon (PH);</li>\n      <li>Cardimed (PH);</li>\n      <li>Cardipene (TH);</li>\n      <li>Carsive (ID);</li>\n      <li>Convertal (PE);</li>\n      <li>Dacarel (PY, UY);</li>\n      <li>Dafil (AR);</li>\n      <li>Flusemide (ES);</li>\n      <li>Karden (AT);</li>\n      <li>Lincil (HN);</li>\n      <li>Loxen (FR, VN);</li>\n      <li>Loxen LP (VN);</li>\n      <li>Nerdipina (ES, PT);</li>\n      <li>Nicafer (ID);</li>\n      <li>Nicardal (IT);</li>\n      <li>Nicardin (PH);</li>\n      <li>Nidaven (ID);</li>\n      <li>Nimicor (IT);</li>\n      <li>Perdipina (IT);</li>\n      <li>Perdipine (CN, ID, JP, KR, PH, TW);</li>\n      <li>Perdipine LA (JP);</li>\n      <li>Ridene (MX);</li>\n      <li>Rydene (BE, LU);</li>\n      <li>Tensilo (ID);</li>\n      <li>Vasonase (ES);</li>\n      <li>Xian Li (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adams HP, del Zoppo G, Alberts MJ, et al, &ldquo;Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups,&rdquo; Stroke, 2007, 38(5):1655-1711. Available at http://stroke.ahajournals.org/cgi/reprint/STROKEAHA.107.181486 17431204</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979896\"></a>American Diabetes Association (ADA). 9. Cardiovascular disease and risk management. <i>Diabetes Care. </i>2017a;40(suppl 1):S75-S87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/27979896/pubmed\" target=\"_blank\" id=\"27979896\">27979896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979898\"></a>American Diabetes Association (ADA). 11. Older adults. <i>Diabetes Care</i>. 2017b;40(suppl 1):S99&ndash;S104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/27979898/pubmed\" target=\"_blank\" id=\"27979898\">27979898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo; <i>J Am Coll Cardiol</i>, 2007, 50(7):e1-157.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/17692738/pubmed\" target=\"_blank\" id=\"17692738\">17692738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baaske DM, DeMay JF, Latona CA, et al, &ldquo;Stability of Nicardipine Hydrochloride in Intravenous Solutions,&rdquo;<i>Am J Health Syst Pharm</i>, 1996, 53(14):1701-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/8827237/pubmed\" target=\"_blank\" id=\"8827237\">8827237</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bartels PA, Hanff LM, Mathot RA, et al, &ldquo;Nicardipine in Pre-Eclamptic Patients: Placental Transfer and Disposition in Breast Milk,&rdquo; <i>BJOG</i>, 2007,114(2):230-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/17166219/pubmed\" target=\"_blank\" id=\"17166219\">17166219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cardene IV (0.1 mg/mL) (nicardipine) [prescribing information]. Bedminister, NJ: EKR Therapeutics; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cardene SR (nicardipine) [prescribing information]. Bedminister, NJ: EKR Therapeutics; June 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dorman T, Thompson DA, Breslow MJ, et al, &ldquo;Nicardipine versus Nitroprusside for Breakthrough Hypertension Following Carotid Endarterectomy,&rdquo; <i>J Clin Anesth</i>, 2001, 13(1):16-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/11259889/pubmed\" target=\"_blank\" id=\"11259889\">11259889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(1):66-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/10669188/pubmed\" target=\"_blank\" id=\"10669188\">10669188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn JT, Mottes TA, Brophy PD, et al, &ldquo;Intravenous Nicardipine for Treatment of Severe Hypertension in Children,&rdquo; <i>J Pediatr</i>, 139(1):38-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/11445792/pubmed\" target=\"_blank\" id=\"11445792\">11445792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(24):e783-e831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/22068434/pubmed\" target=\"_blank\" id=\"22068434\">22068434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jauch EC, Cucchiara B, Adeoye O, et al, &ldquo;Part 11: Adult Stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):818-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/20956227/pubmed\" target=\"_blank\" id=\"20956227\">20956227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jauch EC, Saver JL, Adams HP Jr, et al, &ldquo;Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&rdquo; <i>Stroke</i>, 2013, 44(3):870-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/23370205/pubmed\" target=\"_blank\" id=\"23370205\">23370205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE and Varon J, &ldquo;Hypertensive Crises: Challenges and Management,&rdquo; <i>Chest</i>, 2007, 131(6);1949-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/17565029/pubmed\" target=\"_blank\" id=\"17565029\">17565029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo; <i>Pediatrics</i>, 2004, 114(2 Suppl):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicardipine hydrochloride capsules [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicardipine hydrochloride injection [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nij Bijvank SW and Duvekot JJ, &quot;Nicardipine for the Treatment of Severe Hypertension in Pregnancy: A Review of the Literature,&quot; <i>Obstet Gynecol Surv</i>, 2010, 65(5):341-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/20591204/pubmed\" target=\"_blank\" id=\"20591204\">20591204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pascual-Castroviejo I and Pascual Pascual SI, &ldquo;Nicardipine-Induced Gingival Hyperplasia,&rdquo; <i>Neurologia</i>, 1997, 12(1):37-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/9131913 /pubmed\" target=\"_blank\" id=\"9131913 \">9131913 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Randomized Double-Blind Comparison of a Calcium Antagonist and a Diuretic in Elderly Hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group,&rdquo; <i>Hypertension</i>, 1999, 34(5):1129-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/10567194/pubmed\" target=\"_blank\" id=\"10567194\">10567194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steele RM, Schuna AA, and Schreiber RT, &ldquo;Calcium Antagonist-Induced Gingival Hyperplasia,&rdquo; <i>Ann Intern Med</i>, 1994, 120(8):663-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/8135450/pubmed\" target=\"_blank\" id=\"8135450\">8135450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallin JD, Fletcher E, Ram CV, et al, &ldquo;Intravenous Nicardipine for the Treatment of Severe Hypertension. A Double-Blind, Placebo-Controlled Multicenter Trial,&rdquo; <i>Arch Intern Med</i>, 1989, 149(12):2662-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/2688586/pubmed\" target=\"_blank\" id=\"2688586\">2688586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26. doi: 10.1111/jch.12237.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicardipine-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9697 Version 225.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F201178\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F201215\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F201182\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F201183\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F201184\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F201185\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F201152\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F201138\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F44524584\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F201156\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472949\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472950\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F201155\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730931\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F201224\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F201145\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F201159\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F201142\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F201209\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F201147\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F201175\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F201149\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F201162\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9933181\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9601783\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9933182\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F50404211\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F201141\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F201158\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F201161\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F201163\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9697|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nicardipine-patient-drug-information\" class=\"drug drug_patient\">Nicardipine: Patient drug information</a></li><li><a href=\"topic.htm?path=nicardipine-pediatric-drug-information\" class=\"drug drug_pediatric\">Nicardipine: Pediatric drug information</a></li></ul></div></div>","javascript":null}